Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Molecular Templates

- PMLiVE

Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics

The deal offers BMS a pipeline of investigational medicines to expand its oncology portfolio, including repotrectinib

- PMLiVE

Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies

The companies will work together to develop new therapies to re-establish immune tolerance and repair tissue for those with inflammatory bowel diseases

- PMLiVE

BMS and 2seventy bio announce positive results for multiple myeloma treatment

The results show that Abecma ‘significantly improves’ progression-free survival in relapsed and refractory multiple myeloma

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

- PMLiVE

Boehringer Ingelheim and QUANTRO Therapeutics partner to develop drug candidates

The collaboration aims to offer a long-term strategy to provide breakthrough cancer treatments

- PMLiVE

Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection

Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion

- PMLiVE

Abstract Highlights from EHA 2022 : A Spotlight on CLL

Spotlight on CLLAhead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Prof John Gribben, UK, on the most important abstracts to look out for in...

Medscape Education Global

- PMLiVE

Bristol Myers Squibb launches initiative to ensure disability diversity in clinical trials

Current common clinical trial practices exclude up to a quarter of the US population based on disability status

- PMLiVE

The White House reveals its ‘Cancer Cabinet’ line-up as its Moonshot initiative progresses

The panel includes its new chairperson, Elizabeth Jaffee, Mitchel Berger and Carol Brown

- PMLiVE

Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma

The treatment combination is the first immunotherapy of its kind in over ten years to be made available via the NHS

- PMLiVE

Researchers create ‘world’s largest’ database for predicting cancer treatment response

The database will be available to cancer researchers and clinicians around the world

- PMLiVE

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

The treatment will be available on the NHS as an adjuvant treatment for those at high-risk of recurrence

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links